Modeling and Docking the Endothelin G-Protein-Coupled Receptor

• Published in: Biophysical journal 2000-12, Vol.79 (6), p.3083-3094
• Main Authors: Orry, A.J.W., Wallace, B.A.
• Format: Article
• Language: English
• Subjects: Algorithms; Amino Acid Sequence; Animals; Binding Sites; Cattle; Cell Membrane - ultrastructure; Cells; Endothelin-1 - chemistry; Endothelin-1 - physiology; GTP-Binding Proteins; Humans; Ligands; Membranes; Models, Molecular; Molecular Sequence Data; Nuclear Magnetic Resonance, Biomolecular; Peptide Fragments - chemistry; Peptides; Protein Structure, Secondary; Proteins; Receptor, Endothelin A; Receptors, Endothelin - chemistry; Receptors, Endothelin - physiology; Rhodopsin - chemistry; Sequence Alignment; Sequence Homology, Amino Acid
• ISSN: 0006-3495; 1542-0086
• DOI: 10.1016/S0006-3495(00)76543-X

A model of the endothelin G-protein-coupled receptor (ET A) has been constructed using a segmented approach. The model was produced using a bovine rhodopsin model as a template for the seven transmembrane α-helices. The three cytoplasmic loop regions and the C-terminal region were modeled on NMR structures of corresponding segments from bovine rhodopsin. The three extracellular loops were modeled on homologous loop regions in other proteins of known structure. The N-terminal region was modeled as a three-helix domain based on its homology with a hydrolase protein. To test the model, the FTDOCK algorithm was used to predict the ligand-binding site for the crystal structure of human endothelin. The site of docking is consistent with mutational and biochemical data. The principal sites of interaction in the endothelin ligand all lie on one face of a helix that has been implicated by structure-activity relationship studies as being essential for binding. As further support for the model, attempts to dock bigET, an inactive precursor to endothelin that does not bind to the receptor, found no sites for tight binding. The model of the receptor-ligand complex produced forms a basis for rational drug design of agonists and antagonists for this G-protein-coupled receptor.